Quick Answer
Kura Oncology, Inc. reported R&D Expense of $251.07 million for fiscal year 2025.
Kura Oncology, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $251.07M | +47.7% |
| 2024 | $169.97M | +47.5% |
| 2023 | $115.23M | +24.2% |
| 2022 | $92.81M | +9.6% |
| 2021 | $84.72M | +40.3% |
| 2020 | $60.40M | +26.3% |
| 2019 | $47.83M | +2.2% |
| 2018 | $46.79M | +77.0% |
| 2017 | $26.43M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $67.91M | +62.8% | +8.2% |
| June 30, 2025 | $62.78M | +58.0% | +12.2% |
| March 31, 2025 | $55.97M | +54.3% | +34.2% |
| September 30, 2024 | $41.70M | +42.2% | +5.0% |
| June 30, 2024 | $39.73M | +41.0% | +9.5% |
| March 31, 2024 | $36.27M | +44.0% | +23.7% |
| September 30, 2023 | $29.33M | +17.4% | +4.1% |
| June 30, 2023 | $28.18M | +16.2% | +11.9% |
- Kura Oncology, Inc. showed an increase of +47.7% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Kura Oncology, Inc.’s r&d expense has grown by 850.1% (from $26.43 million to $251.07 million).
- The most recent figure is from Kura Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: